US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLIMB BIO INC

1.42

+0.05003.65%

Post-market: 1.450.0300+2.11%16:47 EDT

Volume:165.34K

Turnover:232.60K

Market Cap:95.96M

PE:-0.89

High:1.45

Open:1.35

Low:1.35

Close:1.37

Loading ...

Overview Company News Filings

President and CEO Aoife Brennan Reports Disposal of Common Shares of Climb Bio Inc

Climb Bio Inc. Files Initial Beneficial Ownership Statement for Chief Business Officer Megan Wilson Perrin

Emily Pimblett, SVP Finance & CAO, Reports Disposal of Climb Bio Inc. Common Shares

Climb Bio Inc. Files Initial Statement of Beneficial Ownership for Cindy Driscoll, Senior Vice President, Finance

Climb Bio Appoints Edgar D. Charles, M.d., MSC as Chief Medical Officer

THOMSON REUTERS

Press Release: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

Climb Bio (CLYM) Initiated with a Buy at Oppenheimer

Climb Bio Initiated at Outperform by Oppenheimer

Oppenheimer Initiates Climb Bio at Outperform With $10 Price Target

MT Newswires Live

Climb Bio Inc. Conducted 2025 Annual Stockholders Meeting

Climb Bio Inc. Announces Leadership Changes: Brett Kaplan Departs, Aoife Brennan Appointed Interim Principal Financial Officer

Climb Bio Inc. Announces Inducement Equity Award Grant for New Employee Under 2025 Inducement Plan

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

BRIEF-Climb Bio Reports First Quarter 2025 Financial Results

Climb Bio Q1 EPS $(0.31) Misses $(0.15) Estimate

Climb Bio Inc. Reports Q1 2025 Financial Results with Increased R&D Expenses Amid Strong Cash Position; No Specific Sales or Net Income Data Provided

Climb Bio Inc - Budoprutug Clinical Trials in Pmn, Itp, Sle on Track for 2025

THOMSON REUTERS

Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CLYM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":1.42,"timestamp":1752523200000,"preClose":1.37,"halted":0,"volume":165338,"hourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.42,"latestTime":"16:47 EDT","volume":560,"amount":792.800008,"timestamp":1752526061907},"delay":0,"floatShares":25491316,"shares":67575767,"eps":-1.59983,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"07-14 19:59:53 EDT","open":1.35,"high":1.45,"low":1.35,"amount":232604.17805520003,"amplitude":0.072993,"askPrice":1.55,"askSize":49,"bidPrice":1.31,"bidSize":1140,"shortable":3,"etf":0,"ttmEps":-1.59983,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1752537600000},"marketStatusCode":4,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":1.37,"preHourTrading":{"tag":"盘前","latestPrice":1.3898,"preClose":1.37,"latestTime":"08:32 EDT","volume":500,"amount":694.9,"timestamp":1752496358565},"postHourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.42,"latestTime":"16:47 EDT","volume":560,"amount":792.800008,"timestamp":1752526061907},"volumeRatio":0.589295},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","floatShares":25491316,"roa":"-18.95%","roe":"-62.04%","lyrEps":-1.5343,"volumeRatio":0.589295,"shares":67575767,"dividePrice":0,"high":1.45,"amplitude":0.072993,"preClose":1.37,"low":1.35,"week52Low":1.05,"pbRate":"0.50","week52High":9.21,"institutionHeld":0,"latestPrice":1.42,"committee":0.917578,"eps":-1.59983,"divideRate":0,"volume":165338,"delay":0,"ttmEps":-1.59983,"open":1.35,"prevYearClose":1.8,"prevWeekClose":1.37,"prevMonthClose":1.24,"prevQuarterClose":1.24,"fiveDayClose":1.26,"twentyDayClose":1.28,"sixtyDayClose":1.36},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLYM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548188769","title":"President and CEO Aoife Brennan Reports Disposal of Common Shares of Climb Bio Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2548188769","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548188769?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:37","pubTimestamp":1751402272,"startTime":"0","endTime":"0","summary":"Aoife Brennan, President and CEO of Climb Bio Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL435ZVk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2545447158","title":"Climb Bio Inc. Files Initial Beneficial Ownership Statement for Chief Business Officer Megan Wilson Perrin","url":"https://stock-news.laohu8.com/highlight/detail?id=2545447158","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545447158?lang=en_us&edition=fundamental","pubTime":"2025-06-24 04:16","pubTimestamp":1750709767,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. has filed an initial statement of beneficial ownership. The filing identifies Megan Wilson Perrin as the beneficial owner, who holds the position of Chief Business Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL4L5Htk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"gpt_icon":0},{"id":"2545170736","title":"Emily Pimblett, SVP Finance & CAO, Reports Disposal of Climb Bio Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170736","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170736?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:20","pubTimestamp":1750450835,"startTime":"0","endTime":"0","summary":"Emily Pimblett, SVP, Finance & CAO of Climb Bio Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLb7FblX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Emily Pimblett, SVP Finance & CAO, Reports Disposal of Climb Bio Inc. Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2545299170","title":"Climb Bio Inc. Files Initial Statement of Beneficial Ownership for Cindy Driscoll, Senior Vice President, Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2545299170","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545299170?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:15","pubTimestamp":1750450556,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing identifies Cindy Driscoll as the beneficial owner, serving in the role of Senior Vice President, Finance. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL1GxTtm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2544796779","title":"Climb Bio Appoints Edgar D. Charles, M.d., MSC as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2544796779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544796779?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:00","pubTimestamp":1750244402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nTUA6GF2BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2544149979","title":"Press Release: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2544149979","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544149979?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:00","pubTimestamp":1750244400,"startTime":"0","endTime":"0","summary":"Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise. Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance. WELLESLEY HILLS, Mass., June 18, 2025  -- Climb Bio, Inc. , a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer  and Cindy J. Driscoll, MBA as Senior Vice President, Finance.Dr. Charles holds a Doctor of Medicine from the University of Alabama School of Medicine, a Master of Science in Clinical and Translational Investigation from Rockefeller University, and a Bachelor of Arts in Economics from the University of Chicago. He completed his Internal Medicine residency and Infectious Diseases fellowship at N","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BMS","BK4539","CLYM"],"gpt_icon":0},{"id":"2542339129","title":"Climb Bio (CLYM) Initiated with a Buy at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2542339129","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542339129?lang=en_us&edition=fundamental","pubTime":"2025-06-10 00:35","pubTimestamp":1749486914,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM – Research Report) received a Buy rating and a $10.00 price target from Oppenheimer analyst Leland Gershell on June 6. The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/climb-bio-clym-initiated-with-a-buy-at-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/climb-bio-clym-initiated-with-a-buy-at-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","CLYM","OPY","BK4139","BK4127"],"gpt_icon":0},{"id":"2541862681","title":"Climb Bio Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2541862681","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541862681?lang=en_us&edition=fundamental","pubTime":"2025-06-07 01:21","pubTimestamp":1749230460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 06, 2025 13:21 ET (17:21 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","OPY"],"gpt_icon":0},{"id":"2541854877","title":"Oppenheimer Initiates Climb Bio at Outperform With $10 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2541854877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541854877?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:13","pubTimestamp":1749208418,"startTime":"0","endTime":"0","summary":"Oppenheimer Initiates Climb Bio at Outperform With $10 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","CLYM"],"gpt_icon":0},{"id":"2541005802","title":"Climb Bio Inc. Conducted 2025 Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541005802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541005802?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:06","pubTimestamp":1749153968,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL5BqBdM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2537220152","title":"Climb Bio Inc. Announces Leadership Changes: Brett Kaplan Departs, Aoife Brennan Appointed Interim Principal Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2537220152","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537220152?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:45","pubTimestamp":1748033120,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. Announces Leadership Changes: Brett Kaplan Departs, Aoife Brennan Appointed Interim Principal Financial Officer. Climb Bio Inc. announced a change in its management team with the departure of Chief Operating Officer Brett Kaplan, M.D., effective May 23, 2025. Following this, Aoife Brennan has been appointed as the interim principal financial officer, effective May 24, 2025. Dr. Brennan has been serving as the President and Chief Executive Officer of Climb Bio since June 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDLbCgV58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2536363031","title":"Climb Bio Inc. Announces Inducement Equity Award Grant for New Employee Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2536363031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536363031?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:35","pubTimestamp":1747686900,"startTime":"0","endTime":"0","summary":"Climb Bio Inc., a biotechnology company focused on developing therapeutics for immune-mediated diseases, announced on May 19, 2025, the granting of an inducement equity award to a new employee under its 2025 Inducement Plan. This award, in line with Nasdaq Listing Rule 5635, comprises a non-statutory stock option to purchase up to 120,000 shares of the company's common stock at an exercise price of $1.27 per share, matching the closing price on the grant date. The option, which has a ten-year term, vests over four years, with 25% becoming exercisable on the first anniversary of the employee's start date and the rest vesting in 36 equal monthly installments, contingent on ongoing employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDLb8jK2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","CLYM","NDAQ","BK4539","LU2210150020.SGD","BK4585","BK4112","LU2095319765.USD","BK4139","BK4588"],"gpt_icon":0},{"id":"2536303526","title":"Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2536303526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536303526?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:34","pubTimestamp":1747686892,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nTUA56RXVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2535025265","title":"BRIEF-Climb Bio Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025265?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:03","pubTimestamp":1747224180,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio Reports First Quarter 2025 Financial Results May 14 (Reuters) - Climb Bio Inc CLYM.O:CLIMB BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESCLIMB BIO INC -","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUAXVTQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"gpt_icon":0},{"id":"2535127047","title":"Climb Bio Q1 EPS $(0.31) Misses $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535127047","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535127047?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:12","pubTimestamp":1747221132,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.15) by 106.67 percent. This is a 416.67 percent decrease over losses of $(0.06) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45402677/climb-bio-q1-eps-0-31-misses-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM"],"gpt_icon":0},{"id":"2535981042","title":"Climb Bio Inc. Reports Q1 2025 Financial Results with Increased R&D Expenses Amid Strong Cash Position; No Specific Sales or Net Income Data Provided","url":"https://stock-news.laohu8.com/highlight/detail?id=2535981042","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535981042?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220451,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. Reports Q1 2025 Financial Results with Increased R&D Expenses Amid Strong Cash Position; No Specific Sales or Net Income Data Provided. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL7Y1rQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","NDAQ"],"gpt_icon":0},{"id":"2535473390","title":"Climb Bio Inc - Budoprutug Clinical Trials in Pmn, Itp, Sle on Track for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535473390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535473390?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUAXVTQF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2535042243","title":"Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042243?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus  on Track to Initiate in 2025. CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025. Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer. Strong Financial Position, with Cash Runway Expected Through 2027. \"2025 is a critical year of execution for Climb Bio and we continue to make excellent progress developing a differentiated pipeline targeting immune-mediated diseases with expansive therapeutic and commercial potential,\" said Aoife Brennan, President and CEO of Climb Bio. \"Our most advanced program, budoprutug, a potential best-in-class anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases, remains on track to initiate clinical studies in ITP and SLE in the coming weeks and in pMN in the second half of 2025. We plan to provide clarity on the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4539","BK4139","CTA","BK4199","ITP","CLYM","SLE"],"gpt_icon":0},{"id":"2526598514","title":"Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX","url":"https://stock-news.laohu8.com/highlight/detail?id=2526598514","media":"Exec Edge","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526598514?lang=en_us&edition=fundamental","pubTime":"2025-04-11 01:08","pubTimestamp":1744304892,"startTime":"0","endTime":"0","summary":"Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates.Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes Fold Holdings, Inc , Climb Bio Inc. , Rex American Resources Corp.  and The ONE Group Hospitality, Inc. .It’s time investors consider harvesting a new generation of profits from the vast American Corn Belt with Rex American Resources Corp. . The leading ethanol manufacturer with a stronghold in the U.S. Midwest may soon reap the benefits of two major investment initiatives. With a fully cash-funded investment budget of $165- $175 million, a fraction of cash on hand, a deliberate growth strategy is combined with financial prudence. With a conservative balance sheet, new growth efforts in motion and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exec-edge-launches-research-coverage-170812519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","QID","FLDDW","BK4138","STKS","BK4112","SQQQ","TQQQ","USAW.SI","BK4209","NVIW.SI","USJW.SI","CLYM","MNQmain","TSYW.SI","PSQ","NQmain","BK4139","BTC","FLD","REX","QLD"],"gpt_icon":1},{"id":"2524191062","title":"Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2524191062","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524191062?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUA7FW8VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ABOS","BK4539","VERV","CLYM","BK7508","LENZ","BK4139","SLDB","IMU.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-09-13","symbol":"CLYM","fiscalQuarterEnding":"2021/06","expectedEps":-2.3,"name":null,"time":"","type":"earning","dateTimestamp":1631505600000,"reportTimeType":"","actualEps":-3.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":2,"updateTime":1749268800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLYM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLYM","date":"2025-07-11","current":-0.981139,"percent":0.809524,"low":-5.682799,"twenty":-2.997362,"median":-1.429631,"eighty":-1.007303,"high":-0.85032,"avg":-2.022236,"sd":1.316272,"marketCap":91227285},"quantilePoints":[{"date":"2024-10-04","current":-5.327624,"twenty":-5.327624,"median":-5.327624,"eighty":-5.327624,"marketCap":342006831},{"date":"2024-10-11","current":-5.369409,"twenty":-5.463426,"median":-5.390302,"eighty":-5.369409,"marketCap":344689237},{"date":"2024-10-18","current":-5.076912,"twenty":-5.494765,"median":-5.390302,"eighty":-5.327624,"marketCap":325912392},{"date":"2024-10-25","current":-4.85754,"twenty":-5.463426,"median":-5.327624,"eighty":-5.014234,"marketCap":311829757},{"date":"2024-10-31","current":-4.094958,"twenty":-5.404927,"median":-5.238831,"eighty":-4.776059,"marketCap":262875838},{"date":"2024-11-08","current":-3.677105,"twenty":-5.390302,"median":-5.014234,"eighty":-4.074065,"marketCap":236051773},{"date":"2024-11-15","current":-3.107258,"twenty":-5.373588,"median":-4.888879,"eighty":-3.806639,"marketCap":214779913},{"date":"2024-11-22","current":-2.917613,"twenty":-5.335981,"median":-4.293438,"eighty":-3.619939,"marketCap":201671280},{"date":"2024-11-29","current":-3.141297,"twenty":-5.327624,"median":-4.220314,"eighty":-3.127681,"marketCap":217132744},{"date":"2024-12-06","current":-2.830085,"twenty":-5.277482,"median":-3.974826,"eighty":-3.040153,"marketCap":195621141},{"date":"2024-12-13","current":-2.742557,"twenty":-5.237786,"median":-3.781569,"eighty":-2.995417,"marketCap":189571003},{"date":"2024-12-20","current":-1.896449,"twenty":-5.13959,"median":-3.671882,"eighty":-2.96235,"marketCap":131086332},{"date":"2024-12-27","current":-2.207661,"twenty":-5.051841,"median":-3.301766,"eighty":-2.921503,"marketCap":152597935},{"date":"2025-01-03","current":-2.013153,"twenty":-5.003788,"median":-3.151022,"eighty":-2.57139,"marketCap":139153183},{"date":"2025-01-10","current":-1.818646,"twenty":-4.962003,"median":-3.124277,"eighty":-2.236837,"marketCap":125708431},{"date":"2025-01-17","current":-1.954801,"twenty":-4.920218,"median":-3.063494,"eighty":-2.032604,"marketCap":135119757},{"date":"2025-01-24","current":-1.770019,"twenty":-4.870076,"median":-3.005142,"eighty":-1.952856,"marketCap":122347243},{"date":"2025-01-31","current":-1.876998,"twenty":-4.531614,"median":-2.995417,"eighty":-1.91979,"marketCap":129741856},{"date":"2025-02-07","current":-1.701941,"twenty":-4.324777,"median":-2.96624,"eighty":-1.892559,"marketCap":117641580},{"date":"2025-02-14","current":-1.546335,"twenty":-4.251653,"median":-2.932201,"eighty":-1.865328,"marketCap":106885778},{"date":"2025-02-21","current":-1.400454,"twenty":-4.228671,"median":-2.873849,"eighty":-1.840042,"marketCap":96802214},{"date":"2025-02-28","current":-1.351828,"twenty":-4.1451,"median":-2.528598,"eighty":-1.818646,"marketCap":93441026},{"date":"2025-03-07","current":-1.429631,"twenty":-4.03228,"median":-2.256288,"eighty":-1.756403,"marketCap":98818927},{"date":"2025-03-14","current":-1.293475,"twenty":-3.971692,"median":-2.18821,"eighty":-1.542445,"marketCap":89407600},{"date":"2025-03-21","current":-1.244848,"twenty":-3.871407,"median":-2.022879,"eighty":-1.474368,"marketCap":86046412},{"date":"2025-03-28","current":-1.159638,"twenty":-3.794104,"median":-1.954801,"eighty":-1.429631,"marketCap":85693751},{"date":"2025-04-04","current":-1.050066,"twenty":-3.724618,"median":-1.940213,"eighty":-1.381004,"marketCap":77596704},{"date":"2025-04-11","current":-1.059197,"twenty":-3.680923,"median":-1.925625,"eighty":-1.357663,"marketCap":78271458},{"date":"2025-04-17","current":-1.150507,"twenty":-3.672927,"median":-1.896449,"eighty":-1.324596,"marketCap":85018997},{"date":"2025-04-25","current":-1.187031,"twenty":-3.573219,"median":-1.876998,"eighty":-1.28764,"marketCap":87718013},{"date":"2025-05-02","current":-1.150507,"twenty":-3.328025,"median":-1.867273,"eighty":-1.252628,"marketCap":85018997},{"date":"2025-05-09","current":-1.088206,"twenty":-3.166583,"median":-1.847822,"eighty":-1.218825,"marketCap":80415162},{"date":"2025-05-16","current":-0.872124,"twenty":-3.152968,"median":-1.818646,"eighty":-1.187031,"marketCap":81090920},{"date":"2025-05-23","current":-0.872124,"twenty":-3.141297,"median":-1.818646,"eighty":-1.164325,"marketCap":81090920},{"date":"2025-05-30","current":-0.886659,"twenty":-3.134489,"median":-1.784607,"eighty":-1.159638,"marketCap":82442435},{"date":"2025-06-06","current":-0.901194,"twenty":-3.10434,"median":-1.750568,"eighty":-1.150507,"marketCap":83793951},{"date":"2025-06-13","current":-0.930265,"twenty":-3.086835,"median":-1.590099,"eighty":-1.125277,"marketCap":86496981},{"date":"2025-06-20","current":-0.893927,"twenty":-3.063494,"median":-1.522022,"eighty":-1.106495,"marketCap":83118193},{"date":"2025-06-27","current":-0.91573,"twenty":-3.014867,"median":-1.478258,"eighty":-1.095721,"marketCap":85145466},{"date":"2025-07-03","current":-0.930265,"twenty":-3.007087,"median":-1.439356,"eighty":-1.066502,"marketCap":86496981},{"date":"2025-07-11","current":-0.981139,"twenty":-2.997362,"median":-1.429631,"eighty":-1.007303,"marketCap":91227285}],"updateTime":1752521735816}}}